IMPROVEMENT OF TUMOUR TREATMENT

摘要

The patent discloses the use of proteins of the endosomal sorting complex required for transport (ESCRT), especially of Hepatocellular Carcinoma Related Protein 1 (HCRP1) as a marker for the efficiency of an anti-EGFR antibody treatment of a tumour patient. If a tumour biopsy sample of the tumour patient reveals an ESCRT protein or mRNA amount equal to or above the amount in normal, non-tumour tissue, then the tumour patient is eligible for the treatment with an anti-EGFR antibody.